Media & Analysis

News
David Munis Zepernick

David Munis Zepernick

Head of Business Development and Public Affairs

Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.

MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.

If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.

MVA-member, Zealand Pharma, builds Global Medical Affairs function with world-renowned experts

Dr. Danilo Verge and Dr. David Kendall, both of whom have decades of experience in the global diabetes space, have joined Zealand Pharma. As Head of Global Medical Affairs at Zealand Pharma, Dr. Danilo Verge will be responsible for all medical activities worldwide related to Zealand Pharma’s metabolic and gastrointestinal franchises including dasiglucagon, glepaglutide and V-Go®. He brings over 20 years of experience from having built and led Medical Affairs functions. Dr. David Kendall has...

MEDICON VALLEY ALLIANCE MEMBER, CHR. HANSEN, WILL CONTINUE TO PIONEER MICROBIAL SCIENCE TO IMPROVE FOOD AND HEALTH, FOR A MORE SUSTAINABLE FUTURE AS PART OF NEW 2025 STRATEGY

MVA-member company, Chr. Hansen, has just released their new ambitious 2025 strategy with the ambition to create a differentiated bioscience leader to improve food and health for a sustainable future In the press release published this week, CEO Mauricio Graber says: “Chr. Hansen has undertaken a tremendous journey since its start as an ingredient supplier to the dairy industry, and I feel very proud to lead a company with such a strong purpose...

Apply for Novo Nordisk Foundation Project Grants in Bioscience and Basic Biomedicine – deadline 2nd of September

The Purpose The objective of the Novo Nordisk Foundation Project Grants in Bioscience and Basic Biomedicine is to promote Danish fundamental research at a high international level within the field of bioscience and basic biomedicine by supporting projects relevant to understanding the human organism and/or basal mechanisms underlying health and disease. The Research Fields The research fields central in the proposed project could be within (but not limited to): Molecular biology, cell biology,...

The European Fight Against The Covid-19 Coronavirus – get an overview of the situation in this recently published Labiotech article

What is the current situation (which changes on a daily basis)? How far are we from a vaccine? Which technologies are involved? Who are the key players? There are more questions than answers out there, but the recently published article "The European Fight Against The Covid-19 Coronavirus"  from our friends and partners from the leading Europe online biotech media, Labiotech.eu, does actually provide everyone interested with a very nice overview of the situation and the most promising private...

New business column about the Danish life science strategy by MVA chairman of the board, Søren Bregenholt and board member and General Manager of AbbVie Scandinavia, Linn Mandahl

Read the newly published MedWatch business column "Think bigger when revisiting the national Danish life science strategy" by Medicon Valley Alliance chairman Søren Bregenholt, CEO Macrophage Pharma and member of the Medicon Valley Alliance Board of Directors and General Manager of AbbVie Scandinavia, Linn Mandahl, if you are just a little bit curious about how and why we should think bigger when revisiting the national Danish life science strategy.

UNION Therapeutics will test candidate found to be 40 times as potent against COVID-19 as remdesivir.

In a press release issued Wednesday 1st of July, MVA-member company, UNION Therapeutics, announces that they have received approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19. Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir Over a number of years, UNION has built a deep understanding of niclosamide and its mechanism of action. Professor Morten...

SmiLe Incubator in Lund launches free online program targeting students and early stage entrepreneurs

Our Friends at SmiLe Incubator is now launching their e-Campus program. The program is aimed at young professionals and academics looking to start or to explore a business or career in the life science sector. SmiLe e-Campus stands out for being the first e-learning program to offer insights from industry experts, thanks to our unique partnership with EIT Health, GE Healthcare and Philips Electronics. The program is free and starts September 7th, and can be attended as a compliment to other...

Interview with CEO, Nils Brünner, MVA-member, Scandion Oncology, about the recent partnership with MVA-member, Alligator Bioscience

When Medicon Valley Alliance Oncology Network was founded back in September 2016 by prof. Nils Brünner, University of Copenhagen, and prof. Carl Borrebaeck, CREATE Health, Lund University, the explicit ambition was to initiate an oncology network focusing on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region. The network should also bring people and ideas together and spur...

MVA Oncology Network members partner up and receive a 800.000 EUR grant from Eurostars

Ole Thastrup, CEO, 2CureX MVA-member, 2cureX, and MVA-member, Scandion Oncology, have just announced a new partnership with Erasmus Medical Centre, Rotterdam and received a  grant of 800.000 EUR from Eurostars, which will be used to study if Scandion Oncology’s drug candidate, SCO -101 can overcome resistance to antiestrogen therapy in metastatic breast cancer patients, and if 2cureX’s IndiTreast test can stratify such patients based on SCO-101 sensitivity. Read full press release...

Interview with Annelie Uvhagen, Director, Business Area Life Sciences, TECHNIA about doing business in the shadow of the COVID-19 crisis

In the recently distributed MVA Newsletter, we asked, Annelie Uvhagen, Director, Business Area Life Sciences, from MVA-member company, TECHNIA a few questions about doing business in the shadow of the COVID-19 crisis. Read the full interview below. Q1) TECHNIA is a new brand with a long international history. What is your interest in the Medicon Valley region? TECHNIA was founded in 1994 and has a long international history of acquisitions to build the 700-man strong global business we are...